Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients.

Pharmaceuticals (Basel) · 2024 · PMC10821420 · PMID 38256950

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

Quality of life, as measured by DLQI, showed a positive trend, with more dupilumab-treated patients reporting ‘not at all’ for each DLQI item compared to the placebo [ 11 , 12 , 13 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.